Correlation between cervical uptake and results of postsurgical radioiodine ablation in patients with thyroid carcinoma

Clinical Nuclear Medicine

Volumn 29, Issue 6, 2004, Pages 358-361

  Rosário, Pedro W S ^a,c   Ribeiro Maia, Frederico Fernandes ^a   Cardoso, Ludmilla David ^a   Barroso, Álvaro ^b   Rezende, Leonardo ^b   Padrão, Eduardo Lanza ^b   Purisch, Saulo ^a  

^a Research Center of the Endocrinology and Metabolism Clinic   (Brazil)

^b Nuclear Medicine Service   (Brazil)

^c CEPCEM   (Brazil)

Author keywords

Cervical uptake; Radioactive iodine; Thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADULT; AGED; ARTICLE; CATHETER ABLATION; CERVICAL SPINE; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSTOPERATIVE COMPLICATION; PREDICTION; RADIATION DOSE; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; THYROID CARCINOMA; THYROIDECTOMY;

ADULT; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NECK; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 2442672852     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000127090.66051.eb     Document Type: Article

References (16)

1. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
3. Schlumberger MJ. Medical progress-papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
4. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451-456.
5. Maxon HR, Englaro EE, Thomas SR. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33: 1132-1136.
6. 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2000;52:765-773.
7. Beierwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of 'ablation of thyroid remnants' with 1-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med. 1984;25:1287-1293.
8. Van Wyngaarden M, McDougall IR. What is the role 1100MBq radioiodine 131 I in the treatment patients with differentiated thyroid cancer? Nucl Med Commun. 1996;17:199-207.
9. Gawkowska-Suwinska M, Turska M, Roskosz J, et al. Early evaluation of treatment effectiveness using 131 iodine radiotherapy in patients with differentiated thyroid cancer. Wiad Lek. 2001;54(suppl):278-288.
10. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer. 1996;77:2574-2580.
11. Goldman JM, Line BR, Aamodt RL, et al. Influence of triiodothyronine withdrawal time on 131-I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab. 1980;50:734-739.
12. Burmeister LA, duCret RP, Mariash CN. Local reactions to radioiodine in the treatment of thyroid cancer. Am J Med. 1991;90:217-222.
13. Alexander C, Bader JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med. 1998;39:1551-1554.
14. 131iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Radiother Oncol. 1998;47:325-330.
15. Arslan N, Ilgan S, Serdengecti M, et al. Post-surgical ablation of thyroid remnants with high-dose (131) I in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2001;22:1021-1027.
16. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab. 2000;85:175-178.